Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)

Clinical Trial ID NCT00050817

PubWeight™ 31.11^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00050817

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.	N Engl J Med	2006	18.25
2	Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.	J Am Coll Cardiol	2007	2.56
3	Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.	Circulation	2010	2.27
4	Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk.	Circulation	2008	2.05
5	Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.	Ann Intern Med	2009	1.76
6	The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease.	Eur Heart J	2009	1.49
7	The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.	Eur Heart J	2012	1.02
8	β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial.	Circ Cardiovasc Qual Outcomes	2014	0.86
9	Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis.	PLoS One	2015	0.75
10	Long-term outcomes in high-risk patients with non-ST-segment elevation myocardial infarction.	J Thromb Thrombolysis	2016	0.75
11	Antiplatelet agents for chronic kidney disease.	Cochrane Database Syst Rev	2022	0.75